NCI-2021-07632

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Patients with an Advanced Solid Tumor

The LuMIERE study is a Phase 1/2 trial happening at multiple centers to test the safety, how the body processes, and how well the drug [177Lu]Lu-FAP-2286 works in patients with advanced solid tumors (cancers that have spread or are difficult to treat). The study is looking at how well the drug is tolerated by patients, how it moves through the body, how much radiation it delivers to the tumor, and if it can help treat these cancers. This is an open-label, non-randomized study, meaning all patients will receive the same treatment, and there is no random selection of treatments.

Phase 1/2 trial: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04939610

Clinical Trial Site: Columbia

To see all available clinical trials click here.